Noxafil FDA Approval History
FDA Approved: Yes (First approved September 15, 2006)
Brand name: Noxafil
Generic name: posaconazole
Company: Schering-Plough Corporation
Treatment for: Aspergillosis, Invasive, Candidemia, Oral Thrush
Noxafil is a triazole antifungal agent indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
Development Timeline for Noxafil
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.